



Eporatio

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
IA/0052	A.7 - Administrative change - Deletion of manufacturing sites	26/09/2023		Annex II and PL	
IB/0051	B.I.z - Quality change - Active substance - Other variation	28/11/2022	n/a		

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



N/0050	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	05/01/2022		Labelling and PL	
PSUSA/1240/202104	Periodic Safety Update EU Single assessment - epoetin theta	02/12/2021	n/a		PRAC Recommendation - maintenance
IB/0048	B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB	11/10/2021	n/a		
II/0047	B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products	22/07/2021	n/a		
IA/0046/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	15/07/2020	n/a		
IB/0045/G	This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation	28/11/2019	n/a		

	B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place				
PSUSA/1240/201804	Periodic Safety Update EU Single assessment - epoetin theta	29/11/2018	n/a		PRAC Recommendation - maintenance
IA/0044	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient	23/11/2018	n/a		
IAIN/0042	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	23/03/2018	29/10/2018	Annex II and PL	
IB/0041	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	07/11/2017	29/10/2018	SmPC and PL	
IB/0040	B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB	05/07/2017	n/a		
II/0035/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name	05/05/2017	n/a		

	<p>and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p> <p>A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release</p> <p>B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method</p>				
IB/0039	B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation	19/04/2017	n/a		
IB/0036	B.I.c.1.a - Change in immediate packaging of the AS - Qualitative and/or quantitative composition	03/03/2017	n/a		
IA/0038	B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information	07/02/2017	n/a		
IB/0037	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	20/01/2017	n/a		
IAIN/0034/G	This was an application for a group of variations.	08/07/2016	15/06/2017	Annex II and	

	<p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p> <p>A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release</p>			PL	
IA/0033	B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State	08/07/2016	n/a		
IA/0032	B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State	08/07/2016	n/a		
IB/0031/G	<p>This was an application for a group of variations.</p> <p>B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol</p> <p>B.II.f.1.e - Stability of FP - Change to an approved stability protocol</p> <p>B.II.f.1.e - Stability of FP - Change to an approved</p>	04/07/2016	15/06/2017	SmPC and Labelling	

	stability protocol				
IB/0030	B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation	29/04/2016	n/a		
IA/0029	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	24/02/2016	n/a		
PSUSA/1240/201504	Periodic Safety Update EU Single assessment - epoetin theta	17/12/2015	22/02/2016	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s) for PSUSA/1240/201504.
IB/0028/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place	12/10/2015	n/a		
IB/0027	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	04/09/2015	n/a		

IA/0026	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient	14/08/2015	n/a		
IB/0024	C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation	24/07/2015	20/08/2015	SmPC and PL	
II/0022	C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	25/06/2015	n/a		
IB/0023/G	This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes	05/05/2015	20/08/2015	SmPC, Labelling and PL	

	tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking				
R/0019	Renewal of the marketing authorisation.	26/06/2014	11/09/2014	SmPC, Labelling and PL	Based on the review of available information, the CHMP is of the opinion that the quality, safety and efficacy of Eporatio/Biopoin continues to be adequately and sufficiently demonstrated and considers that the benefit/risk profile of this medicinal product continues to be favourable.
IAIN/0021/G	This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	12/08/2014	n/a		
IB/0020/G	This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.d.1.c - Stability of AS - Change in the re-test	31/07/2014	n/a		

	period/storage period or storage conditions - Change to an approved stability protocol				
IA/0018	B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information	11/12/2013	n/a		
IB/0017	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	27/11/2013	18/12/2013	SmPC, Annex II and PL	
IB/0015	B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process	05/11/2013	n/a		
N/0014	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	29/10/2013	18/12/2013	PL	
IA/0016	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient	25/10/2013	n/a		
IB/0013	B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation	09/08/2013	n/a		
IAIN/0012	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	18/06/2013	n/a		

IB/0010	B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking	20/12/2012	18/12/2013	SmPC, Labelling and PL	
IB/0009	B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place	08/06/2012	n/a		
IB/0008	B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation	08/06/2012	n/a		
IA/0007/G	This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information	13/04/2012	n/a		
II/0005	to increase the batch size of active substance manufacturing	20/10/2011	20/10/2011		

	B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS				
N/0006	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	14/10/2011	n/a	PL	
II/0004	<p>Introduction of a new Pharmacovigilance System (TEVA DDPS Version 10), including a new Qualified person for Pharmacovigilance.</p> <p>Annex II.B has also been updated with the latest wording as per October 2010 CHMP procedural announcement.</p> <p>C.I.8.a - Introduction of a new Pharmacovigilance system - which has not been assessed by the relevant NCA/EMA for another product of the same MAH</p>	23/06/2011	27/07/2011	Annex II	The MAH has introduced a new pharmacovigilance system used by TEVA Pharmaceutical Industries Ltd., which will be applied for the product Eporatio. The detailed description of this pharmacovigilance system includes information pertaining to the qualified person responsible for pharmacovigilance, the global structure of the pharmacovigilance organisation, company procedures relating to pharmacovigilance activities, global safety databases, links with other organisations, training and the quality management system. The MAH has also taken the opportunity to update Annex II.B with the latest wording as per October 2010 CHMP procedural announcement.
IA/0003	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	30/09/2010	n/a		
IB/0002/G	<p>This was an application for a group of variations.</p> <p>To include the results from the Cochrane meta-analysis in section 5.1 and information on the PRCA in patients with Hepatitis C in section 4.4 of the SmPC.</p> <p>Additionally the MAH took this opportunity to make</p>	22/07/2010	n/a	SmPC	<p>To update Section 5.1 "Pharmacodynamic properties" of the SmPC with the following wording:</p> <p>A patient-level data analysis has also been performed on more than 13,900 cancer patients (chemo-, radio-, chemoradio-, or no therapy) participating in 53 controlled clinical trials involving several epoetins. Meta-analysis of overall survival data produced a hazard ratio point estimate</p>

	<p>minor linguistic amendments to the following languages BG, CS, ET, FI, FR, LV, NL, NO and RO.</p> <p>C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH</p> <p>C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH</p>				<p>of 1.06 in favour of controls (95% CI: 1.00, 1.12; 53 trials and 13,933 patients) and for the cancer patients receiving chemotherapy, the overall survival hazard ratio was 1.04 (95% CI: 0.97, 1.11; 38 trials and 10,441 patients). Meta-analyses also indicate consistently a significantly increased relative risk of thromboembolic events in cancer patients receiving recombinant human erythropoietin (see section 4.4).</p> <p>To update Section 4.4 "Special Warnings and Precautions of Use" of the SmPC with the following wording: A paradoxical decrease in haemoglobin and development of severe anaemia associated with low reticulocyte counts should prompt to discontinue treatment with epoetin and perform anti-erythropoietin antibody testing. Cases have been reported in patients with hepatitis C treated with interferon and ribavirin, when epoetins are used concomitantly. Epoetins are not approved in the management of anaemia associated with hepatitis C.</p>
II/0001	<p>To extend the drug product shelf life.</p> <p>Quality changes</p>	21/01/2010	11/03/2010	SmPC, Labelling and PL	